> ⚠️ Research Use Only: BPC-157 is an investigational research peptide not approved by the FDA for human use. It is not a drug, supplement, or therapeutic. This article is for educational and research purposes only and does not constitute medical advice. Do not use research peptides for self-experimentation.
---
# BPC-157 Dosage & Research Protocol Guide 2026
BPC-157 is one of the most studied synthetic peptides in preclinical research, with an extensive body of literature examining its effects on tissue healing, inflammation, and organ protection. Yet despite hundreds of published studies, the question researchers most frequently ask is: what dosage parameters does the literature actually use?
This guide synthesizes peer-reviewed data on BPC-157 dosing, administration routes, and research protocols — strictly for educational and research planning purposes.
1. What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a pentadecapeptide — a chain of 15 amino acids — derived from a protective protein naturally found in gastric juice. Its full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV).
Unlike many research peptides, BPC-157 was not engineered from a growth hormone releasing pathway. It was first described in the 1990s by researchers studying gastric cytoprotection, and subsequent studies expanded its scope to musculoskeletal tissue, the central nervous system, and vascular biology.
For a comprehensive overview of BPC-157 mechanism of action and pharmacology, see the BPC-157 complete research profile.
Why BPC-157 Attracts Research Interest
Preclinical studies have reported BPC-157 activity in several model systems:
- •Tendon and ligament healing (transection models in rats)
- •Inflammatory bowel disease models
- •Bone healing in segmental defect models
- •Neurological protection in TBI and spinal cord injury models
- •Systemic organ protection under various stress conditions
All of this preclinical data comes from animal studies. No Phase II or Phase III human clinical trials have been completed as of 2026.
---
2. BPC-157 in Research: What Studies Actually Report
The published literature uses a wide range of dosing parameters depending on the model system, route of administration, and research objective. Below is a synthesis of dosage parameters reported across peer-reviewed studies.
Dosage Range Observed in Animal Studies
| Route | Dose Range Reported | Frequency | Model |
|---|---|---|---|
| Intraperitoneal (IP) injection | 10–100 mcg/kg | Once daily | Rat tendon, bowel, bone models |
| Subcutaneous (SubQ) injection | 10–200 mcg/kg | Once or twice daily | Rat/mouse wound, organ models |
| Oral/drinking water | 10–100 mcg/kg | Daily in drinking water | GI models, systemic effects |
| Intragastric | 10–1,000 mcg/kg | Acute or chronic dosing | GI cytoprotection models |
| Topical/local | Variable | Single or repeat application | Local wound models |
Key finding from the literature: Most studies demonstrating statistically significant effects cluster in the 10–100 mcg/kg range administered daily. Higher doses (500–1,000 mcg/kg) are typically found in acute protection studies rather than chronic dosing protocols.
Primary references:
- •Chang CH, et al. (2011). "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology, 110(3):774-80. PMID 21030672
- •Mateescu DM, et al. (2026). "BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers." Pharmaceutics. PMID 42198317
- •Józwiak M, et al. (2025). "Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review." Pharmaceuticals. PMID 40005999
Route of Administration in Research Context
Intraperitoneal (IP) injection is the most common route in rodent studies, allowing precise, reproducible dosing. It is a standard preclinical research technique not applicable to human administration.
Subcutaneous (SubQ) injection is also well-represented in the literature, particularly in musculoskeletal models. SubQ administration is generally considered to produce more gradual systemic absorption compared to IP.
Oral administration (dissolved in drinking water) has been studied specifically for GI-related applications. Studies from the Zagreb group have examined whether oral BPC-157 retains systemic activity, with some data suggesting peripheral effects extend beyond the GI tract even when administered orally.
Local/intralesional injection has been used in targeted tissue healing studies, particularly tendon and ligament models.
---
3. Reconstitution Protocol (Research Use)
BPC-157 is sold in lyophilized (freeze-dried) powder form for research purposes. Proper reconstitution is essential for maintaining peptide integrity and accurate dosing in research applications.
What You Need
- •BPC-157 lyophilized powder (e.g., 5 mg vial)
- •Bacteriostatic water (0.9% benzyl alcohol in sterile water) — preferred for multi-use vials; inhibits bacterial growth
- •Sterile water for injection — acceptable for single-use reconstitution
- •Appropriately sized syringes (1 mL insulin syringes for small volumes)
- •Alcohol swabs
> Why bacteriostatic water? Standard sterile water lacks a preservative. Once a vial is punctured, bacterial contamination can occur within days. Bacteriostatic water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable life of the reconstituted peptide to approximately 4 weeks when refrigerated (2-8 degrees C).
Reconstitution Steps
1. Calculate your target concentration. A common research concentration is 1 mg/mL (1,000 mcg/mL). For a 5 mg vial: add 5 mL of bacteriostatic water.
- Higher concentration (2 mg/mL): add 2.5 mL bac water — useful when working with small injection volumes
- Lower concentration (0.5 mg/mL): add 10 mL bac water — useful for very precise low-dose research
2. Swab the vial top with an alcohol swab and allow to dry (15–30 seconds).
3. Draw up the bacteriostatic water into your syringe.
4. Inject the water slowly along the inner glass wall — do not aim the stream directly at the powder cake. This preserves peptide structure and prevents foaming.
5. Do not shake. Gently swirl or roll the vial until the powder is fully dissolved. The solution should be clear and colorless. Slight cloudiness can indicate degradation or an excipient — check your source's COA.
6. Label the vial with reconstitution date, concentration, and storage conditions.
Storage After Reconstitution
| Condition | Duration |
|---|---|
| Refrigerated (2-8 degrees C) | Up to 4 weeks (with bac water) |
| Frozen (-20 degrees C) | Up to 3 months (avoid repeated freeze-thaw) |
| Room temperature | Not recommended (accelerates degradation) |
Lyophilized (unreconstituted) BPC-157 should be stored in a cool, dry location away from light. Most research suppliers report 24+ month stability in lyophilized form when properly stored.
Certificate of Analysis (COA): Research-grade BPC-157 should be accompanied by HPLC purity data and mass spectrometry confirmation. A minimum purity of 98% is standard for research-quality peptides.
---
4. Dosage Parameters Used in Research
This section summarizes how published research has framed dosing parameters. These are not recommendations — they are descriptions of what the literature reports.
Weight-Based Dosing (Animal Studies)
The vast majority of published BPC-157 studies use weight-based dosing in mcg/kg. The most commonly cited range for demonstrating activity in musculoskeletal healing models is 10–100 mcg/kg/day.
How Researchers Calculate Volume for Injection
Using a 1 mg/mL (1,000 mcg/mL) concentration as the example:
| Target dose (mcg/kg) | Body weight | Total dose (mcg) | Volume to inject |
|---|---|---|---|
| 10 mcg/kg | 300g rat | 3 mcg | 3 mcL |
| 100 mcg/kg | 300g rat | 30 mcg | 30 mcL |
| 200 mcg/kg | 300g rat | 60 mcg | 60 mcL |
For precise small-volume work, researchers often use a higher stock concentration (e.g., 5 mg/mL) to avoid working with very small injection volumes.
For volume math in research protocols, our peptide reconstitution calculator can help once a target dose and concentration are defined.
Duration of Protocols in the Literature
Study durations in published research vary considerably:
- •Acute studies: Single dose to 7 days (e.g., organ protection models)
- •Subchronic: 2–4 weeks (common for musculoskeletal healing models)
- •Chronic: 4–12 weeks (GI, systemic, and neurological models)
Chang et al. (2011; PMID 21030672) demonstrated tendon healing effects with 14-day subcutaneous dosing protocols. Chronic dosing models extending up to 90 days have been reported in the animal literature without documented toxicity.
---
5. Injection Sites in Research Context
For subcutaneous administration in animal models, injection sites are typically the dorsal flank or scruff region — standard preclinical practice that minimizes interference with the tissue being studied.
SubQ Technique Overview (General Research Context)
Subcutaneous injection delivers the peptide into the fatty tissue layer beneath the skin, allowing for gradual absorption into systemic circulation. In standard research practice:
1. Swab the injection site with an alcohol swab; allow to dry
2. Pinch a fold of skin to elevate the subcutaneous layer
3. Insert needle at approximately 45 degrees angle
4. Aspirate briefly to confirm non-vascular placement (no blood return)
5. Inject slowly and steadily
6. Withdraw the needle and apply gentle pressure — do not rub (minimizes local peptide dispersion)
Rotate injection sites across sessions to prevent local tissue changes at repeated injection sites.
> Warning: These techniques are described as general subcutaneous injection methodology for research context. They are not instructions for human self-administration.
---
6. BPC-157 Forms: Peptide vs. Capsules vs. Nasal Spray
Research-grade BPC-157 is available in several physical forms. The evidence base differs substantially across forms.
Injectable Peptide (Lyophilized)
Most extensively studied form. The published literature overwhelmingly uses injectable (IP or SubQ) administration in animal models. This route provides the most predictable pharmacokinetic profile and bioavailability.
Quality indicators:
- •HPLC purity 98% or above
- •Mass spectrometry verification of molecular weight (MW: 1419.55 g/mol)
- •Endotoxin testing (LAL test) for sterile research applications
- •Produced under GMP or research-grade manufacturing conditions
Oral/Capsule Form
Some vendors offer BPC-157 in encapsulated form. The scientific rationale for oral activity has some preclinical support — studies from Sikiric's group have examined intragastric administration — but the peptide is expected to undergo significant GI proteolytic degradation.
Oral bioavailability data in humans does not exist in peer-reviewed literature. For GI-focused research applications (e.g., studying gut lining effects), oral delivery has a theoretical rationale. For systemic endpoints, injectable forms have a stronger evidence basis.
Nasal Spray
Nasal (intranasal) BPC-157 formulations are sold by some research vendors. The mucosal absorption pathway bypasses GI degradation, but peer-reviewed pharmacokinetic data for intranasal BPC-157 is minimal as of 2026.
BPC-157 Acetate vs. Arginate Salt
Many suppliers now offer BPC-157 in "arginate" or "arginate salt" form, marketed as more stable. The arginate version uses an arginine counter-ion to improve hygroscopicity and shelf stability of the lyophilized powder. The peptide sequence is identical to standard BPC-157 acetate. Published studies do not demonstrate differential activity between the two forms in animal models.
---
7. Where to Find BPC-157 for Research
For researchers sourcing BPC-157, quality verification is the primary criterion. Key factors:
- •Third-party HPLC and mass spec COAs (not just vendor-issued)
- •Documented sterility and endotoxin testing
- •Transparent sourcing and manufacturing disclosures
The BPC-157 supplier comparison page on Peptides.SO lists verified research suppliers with price comparisons, COA availability, and community quality ratings.
For researchers also studying synergistic tissue-healing protocols, TB-500 (Thymosin Beta-4) is frequently examined alongside BPC-157 in musculoskeletal healing literature.
---
8. Frequently Asked Questions
Q: Does the literature show BPC-157 has different effects at different doses?
Yes — multiple studies have examined dose-response relationships. The Zagreb group has published studies showing activity across a wide range (10–1,000 mcg/kg), with some models showing saturable effects at higher doses. The practical dose range demonstrating effect in most healing models is 10–100 mcg/kg/day.
Q: How does BPC-157 differ from TB-500 in research protocols?
TB-500 (Thymosin Beta-4) and BPC-157 are often co-studied in recovery models. TB-500 is a larger peptide (43 amino acids) that operates via actin-binding and angiogenic mechanisms distinct from BPC-157's growth factor receptor modulation. Some researchers use both peptides in combined protocols. See our BPC-157 vs TB-500 comparison for a detailed breakdown.
Q: Is there human clinical trial data on BPC-157?
BPC-157 has not completed large-scale human clinical trials as of 2026. Phase I safety data exists from early studies in Croatia, but Phase II efficacy trials are not available in public databases. All efficacy data cited in this article is from preclinical (animal) models.
Q: Does the form of BPC-157 (acetate vs. arginate) affect research outcomes?
No studies have demonstrated differential activity. The arginate form is chemically identical in the active peptide sequence; the difference is in the counter-ion used for the salt form, which affects stability and hygroscopicity of the dry powder.
Q: What is the shelf life of reconstituted BPC-157?
Reconstituted BPC-157 in bacteriostatic water stored at 2-8 degrees C is generally considered stable for up to 4 weeks. Unreconstituted lyophilized powder stored at -20 degrees C has reported stability of 24+ months from most manufacturers. Multiple freeze-thaw cycles degrade peptide integrity.
Q: Can a peptide calculator help with dose preparation?
Yes — our peptide reconstitution calculator is specifically designed for calculating injection volumes, concentrations, and reconstitution math. Enter your vial size, target concentration, and target dose to get the exact volume to inject.
---
Research Resources
- •BPC-157 Complete Research Guide — Full mechanism, evidence review, and supplier comparison
- •TB-500 Research Profile — Thymosin Beta-4, frequently co-studied with BPC-157
- •Peptide Reconstitution Calculator — Reconstitution math and volume calculations
- •TB-500 Dosage & Research Protocol Guide — Companion dosing guide for the most common BPC-157 co-compound
- •BPC-157 + TB-500 Stack Protocol Guide — Combined dosing schedule for both peptides
- •BPC-157 vs TB-500: Side-by-Side Comparison — Which peptide for which research application?
- •How to Track Peptide Dosing Schedules — Research logging methodology
---
References
1. Chang CH, Tsai WC, et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3):774-80. PMID 21030672
2. Mateescu DM, Gavrilescu DM, et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. PMID 42198317
3. Józwiak M, Bauer M, et al. (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide - Literature and Patent Review. Pharmaceuticals (Basel). PMID 40005999
Note: this reference list was corrected 2026-08-09 — the prior version cited PMIDs that, on verification against NCBI PubMed, resolved to unrelated papers. Only citations independently verified via NCBI eutils are retained.
---
> Full Research Use Only Disclaimer: BPC-157 is an investigational synthetic peptide intended solely for preclinical research purposes. It is not approved by the U.S. Food and Drug Administration (FDA) or any equivalent regulatory body for human therapeutic use. The information in this article is derived from peer-reviewed preclinical literature and is presented for educational purposes only. Nothing in this article constitutes medical advice, treatment recommendations, or encouragement to use BPC-157 or any research peptide in humans or animals outside of a properly supervised research context. Researchers should comply with all applicable local, state, and federal regulations regarding research peptide use, handling, and storage. Peptides.SO does not endorse, encourage, or facilitate the use of research peptides for human self-experimentation.